Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University, Atlanta, Georgia 30303, USA.
Am J Med Sci. 2011 Apr;341(4):325-32. doi: 10.1097/MAJ.0b013e3181f30dee.
Critical illnesses continue to be major causes of morbidity and mortality worldwide. Recent investigations show that stem cells may be beneficial as prognostic biomarkers and novel therapeutic strategies in these syndromes. This article reviews the use of stem cells in sepsis and acute lung injury as prognostic biomarkers and also as a potential for exogenous cell-based therapy.
A directed search of the medical literature was done using PubMed and OVID to evaluate topics related to pathophysiology of sepsis and acute lung injury, in addition to the characterization and utilization of stem cells in these diseases.
Stem cells have shown significant promise in the field of critical care medicine both for prognostication and treatment strategies. Although recent studies have been done to describe the mechanistic pathways of stem cells in critical illness, further investigation is necessary to fully delineate the mechanisms behind a stem cell's immunomodulatory characteristics and its ability to mobilize and engraft in tissues.
危重病仍然是全球发病率和死亡率的主要原因。最近的调查表明,干细胞可能作为这些综合征的预后生物标志物和新的治疗策略有益。本文综述了干细胞在脓毒症和急性肺损伤中的应用,作为预后生物标志物,以及作为外源性基于细胞的治疗的潜在用途。
使用 PubMed 和 OVID 进行定向搜索医学文献,以评估与脓毒症和急性肺损伤的病理生理学相关的主题,以及这些疾病中干细胞的特征和利用。
干细胞在重症监护医学领域具有很大的应用前景,既可以用于预后,也可以用于治疗策略。尽管最近已经进行了一些研究来描述干细胞在危重病中的机制途径,但仍需要进一步研究来充分阐明干细胞的免疫调节特性及其在组织中动员和植入的机制。